Company: INVUP
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001193
Chunk: 1795

Company: Investview, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 4
Chunk 1795
---
 for surrender and cancellation an aggregate of 472,374,710
shares of the Company’s common stock from Ryan Smith and Chad Miller and certain of their respective affiliates and family members.
These shares were purchased for an aggregate purchase price of $3,571,146, equating to a price of $0.007559985 per share; representing
a discount of approximately 57.6% to the average market price at the time of the closing. One-eighth of the purchase price was paid within
seven (7) days of the closing, with the balance payable in a series of equal quarterly payments over seven (7) consecutive quarters thereafter.
See Item 13 of this Form 10-K for additional details on the transaction.

Finally, on October 25, 2024, we announced that we entered into an agreement
to purchase from certain non-affiliated shareholders, in a private transaction, a total of 121 million shares of our common stock. Closing
under the share purchase transaction, however, was subject to certain customary and standard closing conditions, including, primarily,
the delivery of the purchased shares to the Company at a closing to be conducted on or before an outside termination date of February
23, 2025. As of the date of this Report, the sellers in the transaction have been unable to arrange delivery of the shares. Accordingly,
we cannot assure that the transaction will occur as announced. We have reserved our rights under the agreement.

Acquisition
of Business of Opencash

On
March 18, 2024, we announced the acquisition of Opencash, an early-stage registered broker-dealer that plans to offer investors an online
platform to enable self-directed retail brokerage and other related services.

Acquisition
of Business of Renu

On
October 11, 2024, we acquired substantially all of the business and assets of Renu Labs.
The total purchase price of Renu Labs was $1,780,000. As part of this acquisition, we also issued 5,000,0000 stock options to the principal
of Renu Labs, which options are scheduled to vest in equal amounts over a five-year period, at an exercise price of $0.05 per share with
a ten-year life.

Settlement
of Outstanding Matter with the SEC

During
November 2021, we received a subpoena from the United States Securities and Exchange Commission (“SEC”) for the production
of documents. The SEC order, the factual and legal findings of which we neither